Consensus recommendations from the American Acne & Rosacea society on the management of rosacea, part 5: A guide on the management of rosacea

Cutis

Volumn 93, Issue 3, 2014, Pages 134-138

  Del Rosso, James Q ^a,b,c   Thiboutot, Diane ^d   Gallo, Richard ^e   Webster, Guy ^f   Tanghetti, Emil ^g   Eichenfield, Lawrence F ^h,i   Stein Gold, Linda ^j   Berson, Diane ^k   Zaenglein, Andrea ^d  

^a TOURO UNIVERSITY NEVADA   (United States)

^b Las Vegas Skin and Cancer Clinics West Dermatology Group   (United States)

^c Penn State University Medical Center ^*

^d PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

^g Center for Dermatology and Laser Surgery   (United States)

^h RADY CHILDREN'S HOSPITAL   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j HENRY FORD HOSPITAL   (United States)

^k NEW YORK PRESBYTERIAN HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIINFECTIVE AGENT; AZELAIC ACID; BRIMONIDINE; DERMATOLOGICAL AGENT; DICARBOXYLIC ACID; DOXYCYCLINE; METRONIDAZOLE; QUINOXALINE DERIVATIVE;

COMPLICATION; CONSENSUS; ERYTHEMA; HUMAN; INTRADERMAL DRUG ADMINISTRATION; MEDICAL SOCIETY; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; ROSACEA; SEVERITY OF ILLNESS INDEX;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ANTI-INFECTIVE AGENTS; CONSENSUS; DERMATOLOGIC AGENTS; DICARBOXYLIC ACIDS; DOXYCYCLINE; ERYTHEMA; HUMANS; METRONIDAZOLE; QUINOXALINES; ROSACEA; SEVERITY OF ILLNESS INDEX; SOCIETIES, MEDICAL;

EID: 84897763945     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Odom R, Dahl M, Dover J, et al; National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. Standard management options for rosacea, part 2: options according to rosacea subtype. Cutis. 2009;84:97-104.
2. Del Rosso JQ, Baldwin H, Webster G; American Acne & Rosacea Society. American Acne & Rosacea Society rosacea medical management guidelines. J Drugs Dermatol. 2008;7:531-533.
3. Steinhoff M, Buddenkotte J, Aubert J, et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Invest Dermatol Symp Proc. 2011;15:2-11.
4. Yamasaki K, Gallo RL. The molecular pathology of rosacea [published online ahead of print May 29, 2009]. J Dermatol Sci. 2009;55:77-81.
5. Fleischer AB Jr. Inflammation in rosacea and acne: implications for patient care. J Drugs Dermatol. 2011;10:614-620.
6. Del Rosso JQ. Advances in understanding and managing rosacea: part 1: connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema. J Clin Aesthet Dermatol. 2012;5:16-25.
7. Del Rosso JQ. Advances in understanding and managing rosacea: part 2: the central role, evaluation, and management of diffuse and persistent facial erythema of rosacea. J Clin Aesthet Dermatol. 2012;5:26-36.
8. Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 1: a status report on the disease state, general measures, and adjunctive skin care. Cutis. 2013;92:234-240.
9. Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents. Cutis. 2013;92:277-284.
10. Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 3: a status report on systemic therapies. Cutis. 2014;93:18-28.
11. Tanghetti E, Del Rosso JQ, Thiboutot D, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 4: a status report on physical modalities and devices. Cutis. 2014;93:71-76.
12. van Zuuren EJ, Kramer S, Carter B, et al. Interventions for rosacea. Cochrane Database Syst Rev. 2011;CD003262.
13. Wilkin J, Dahl M, Detmar M, et al; National Rosacea Society Expert Committee. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2004;50:907-912.
14. Del Rosso JQ, Baum EW. Comprehensive medical management of rosacea: an interim study report and literature review. J Clin Aesthet Dermatol. 2008;1:20-25.
15. Kennedy Carney C, Cantrell W, Elewski BE. Rosacea: a review of current topical, systemic and light-based therapies. G Ital Dermatol Venereol. 2009;144:673-688.
16. Kim S, Michaels BD, Kim GK, et al. Systemic antibacterial agents. In: Wolverton SE. Comprehensive Dermatologic Drug Therapy. 3rd ed. Philadelphia, PA: Elsevier Saunders; 2013:61-97.
17. Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. Cutis. 2007;79(suppl 6):9-25.
18. Bhatia ND, Del Rosso JQ. Optimal management of papulopustular rosacea: rationale for combination therapy. J Drugs Dermatol. 2012;11:838-844.
19. Del Rosso JQ, Bruce S, Jarratt M, et al. Efficacy of topical azelaic acid gel (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild-to-moderate papulopustular rosacea. J Drugs Dermatol. 2010;9:607-613.
20. Fowler J, Jarratt M, Moore A, et al. Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicenter, randomized and vehicle controlled studies. Br J Dermatol. 2012;166:633-641.
21. Del Rosso JQ. Management of facial erythema of rosacea: what is the role of topical α-adrenergic receptor agonist therapy? J Am Acad Dermatol. 2013;69(6, suppl 1):S44-S56.
22. Dahl MV, Katz HI, Krueger GG, et al. Topical metronidazole maintains remissions of rosacea. Arch Dermatol. 1998;134:679-683.
23. Thiboutot DM, Fleischer AB, Del Rosso JQ, et al. A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy. J Drugs Dermatol. 2009;8:639-648.
24. Oracea (doxycycline USP) capsules 40 mg (30 mg immediate-release and 10 mg delayed-release beads)[package insert]. Fort Worth, TX: Galderma Laboratories, LP; 2013.
25. Preshaw PM, Novak MJ, Mellonig J, et al. Modified-release subantimicrobial dose doxycycline enhances scaling and root planing in subjects with periodontal disease. J Periodontol. 2008;79:440-452.
26. Rosen T. Antibiotic resistance: an editorial review with recommendations. J Drugs Dermatol. 2011;10:724-733.
27. Del Rosso JQ, Leyden JJ. Status report on antibiotic resistance: implications for the dermatologist. Dermatol Clin. 2007;25:127-132.
28. Ogawa R, Echizen H. Clinically significant drug interactions with antacids: an update. Drugs. 2011;71:1839-1864.
29. Del Rosso JQ. Oral antibiotic drug interactions of clinical significance to dermatologists. Dermatol Clin. 2009;27:91-94.
30. Kanada KN, Nakatsuji T, Gallo RL. Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin. J Invest Dermatol. 2012;132:1435-1442.
31. Coda AB, Hata T, Miller J, et al. Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel. J Am Acad Dermatol. 2013;69:570-577.